Danshen (Salvia miltiorrhiza Bunge) is widely used in
traditional Chinese medicine. In our study, the in vivo protective effect of danshen in
prostate cancer patients was validated through data from the National Health Insurance Research Database in Taiwan. In vitro, we discovered that
dihydroisotanshinone I (DT), a bioactive compound present in danshen, can inhibit the migration of both
androgen-dependent and
androgen-independent
prostate cancer cells. In addition, we noted that DT substantially inhibited the migratory ability of
prostate cancer cells in both a macrophage-
conditioned medium and macrophage/
prostate cancer coculture medium. Mechanistically, DT both diminished the ability of
prostate cancer cells to recruit macrophages and reduced the secretion of
chemokine (C-C motif) ligand 2 (CCL2) from both macrophages and
prostate cancer cells in a dose-dependent manner. Moreover, DT inhibited the
protein expression of p-STAT3 and decreased the translocation of STAT3 into nuclear
chromatin. DT also suppressed the expression of
tumor epithelial-mesenchymal transition genes, including RhoA and SNAI1. In conclusion, danshen can prolong the survival rate of
prostate cancer patients in Taiwan. Furthermore, DT can inhibit the migration of
prostate cancer cells by interrupting the crosstalk between
prostate cancer cells and macrophages via the inhibition of the CCL2/STAT3 axis. These results may provide the basis for a new therapeutic approach toward the treatment of
prostate cancer progression.